Physician profile
Don A Tran
NPI 1215079389
$687.68
in general payments reported to CMS, 2019-2025
13 companies · $40.70 in 2025
The $40.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2021: $64.48 · 2023: $275 · 2024: $83.01 · 2025: $40.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $247.01 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $91.65 | 2019 | |
| Angiodynamics, INC. | $64.48 | 2021 | |
| Lilly USA, LLC | $62.33 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $37.16 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $32.33 | 2019 | |
| Abbvie INC. | $31.86 | 2023-2024 | Qulipta |
| Pfizer INC. | $30.93 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $26.14 | 2023 | Arcalyst |
| Exact Sciences Corporation | $17.65 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.21 | 2019 | |
| Bausch & Lomb Americas INC. | $14.48 | 2024 | Miebo |
| Novo Nordisk INC | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.